Gyre Therapeutics
GYRE
79 hedge funds and large institutions have $81.8M invested in Gyre Therapeutics in 2020 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 2 closing their positions.
1,650% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 2
74% more capital invested
Capital invested by funds: $47M → $81.8M (+$34.8M)
72% more funds holding
Funds holding: 46 → 79 (+33)
61% more call options, than puts
Call options by funds: $875K | Put options by funds: $544K
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
0.19% less ownership
Funds ownership: 8.61% → 8.42% (-0.19%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$5.04M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.35M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$2.24M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.7M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.37M |
Top Sellers
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.95M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$1.43M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.3M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$844K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$644K |
GYRE Hedge Fund Activity: Q2 2020 in Review
79 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2020, worth a combined $81.8M — up 74% from $47M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new GYRE positions and 2 closed out — a net gain of 33 holders — while 22 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $5.04M. The largest seller was Stonepine Capital Management, cutting an estimated $2.95M.
- 79 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2020, up from 46 in Q1 2020.
- Funds reported $81.8M of Gyre Therapeutics stock for Q2 2020, up 74% quarter-over-quarter.
- 35 funds opened new Gyre Therapeutics positions in Q2 2020 and 2 closed out, a net change of +33 holders.
- The largest Gyre Therapeutics buyer in Q2 2020 was BlackRock, an estimated $5.04M added.
- The largest Gyre Therapeutics seller in Q2 2020 was Stonepine Capital Management, an estimated $2.95M sold.
Based on aggregated 13F filings for Q2 2020.